| Cao, Yu |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT06136507: Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 76 | RoW | FRSW107, Recombinant Human Coagulation Factor Ⅷ，Fc Fusion Protein for Injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 12/26 | 12/26 | | |
NCT05265286: A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection |
|
|
| Completed | 2 | 15 | RoW | FRSW117, PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 08/22 | 08/22 | | |
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
NCT06021574: A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody |
|
|
| Completed | 1 | 40 | RoW | VDJ001, Placebo | The Affiliated Hospital of Qingdao University, Beijing VDJBio Co., LTD. | Healthy | 01/20 | 01/20 | | |
NCT04951765: Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects |
|
|
| Recruiting | 1 | 24 | RoW | XZP-3287 | Xuanzhu Biopharmaceutical Co., Ltd. | Healthy | 08/21 | 12/21 | | |
NCT05034120: Food Effect and Mass Balance Study of XZP-3621 Tablets |
|
|
| Not yet recruiting | 1 | 34 | RoW | XZP-3621 | Xuanzhu Biopharmaceutical Co., Ltd. | Healthy | 11/21 | 12/21 | | |
| Recruiting | 1 | 12 | RoW | CuminUP30, Curcumin capsules | The Affiliated Hospital of Qingdao University, Chenland Nutritionals Inc. | Healthy Adult Subjects | 04/22 | 12/22 | | |
NCT05486598: A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects |
|
|
| Recruiting | 1 | 16 | RoW | AL8326 tablets, AL8326 | Advenchen Laboratories Nanjing Ltd. | Diet, High-Fat, Pharmacokinetics | 12/22 | 12/22 | | |
NCT05398510: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject |
|
|
| Completed | 1 | 61 | RoW | SHR-2010 injection, SHR-2010 injection placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | IgA Nephropathy | 03/23 | 03/23 | | |
NCT05380934: A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects |
|
|
| Completed | 1 | 63 | RoW | TQH3821 tablets, TQH3821 tablets (Placebo), Methotrexate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 05/23 | 05/23 | | |
| Not yet recruiting | 1 | 72 | RoW | XZP-3621 tablet and itraconazole oral liquid (for Arm1), XZP-3621 tablet and Rifampicin capsules (For Arm 2), XZP-3621 tablet and esomeprazole tablet (For Arm3) | Xuanzhu Biopharmaceutical Co., Ltd. | Healthy Subjects | 04/23 | 08/23 | | |
NCT05505955: Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency |
|
|
| Completed | 1 | 83 | RoW | HRS-5965, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Glomerulonephritis | 11/23 | 11/23 | | |
NCT05409326: A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 48 | RoW | TQH2722 injection, Placebo to match TQH2722 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Atopic Dermatitis | 06/23 | 08/23 | | |
YY-BFNT-2023, NCT06589921: Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions |
|
|
| Completed | 1 | 24 | RoW | Pirfenidone Modified-Release Tablets, Pirfenidone Tablets | Overseas Pharmaceuticals, Ltd. | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
| Not yet recruiting | 1 | 40 | RoW | TQB3454 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/23 | 12/23 | | |
NCT06126718: Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects |
|
|
| Not yet recruiting | 1 | 88 | NA | BR201, Cosentyx（Secukinumab ） | BioRay Pharmaceutical Co., Ltd. | Psoriasis | 06/24 | 08/24 | | |
NCT05942612: A Phase I Study of SHR -2001 in Healthy Subjects |
|
|
| Recruiting | 1 | 49 | RoW | SHR-2001, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Healthy | 12/23 | 12/23 | | |
NCT06186414: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC |
|
|
| Recruiting | 1 | 152 | RoW | SIM0237, SIM0237 and BCG | Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd. | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 01/27 | 12/30 | | |
NCT06506175: Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 144 | RoW | HRS9531 tablets | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obese, Type 2 Diabetes | 11/24 | 11/24 | | |
NCT06569381: Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions |
|
|
| Not yet recruiting | 1 | 18 | RoW | Pirfenidone Modified-Release Tablets | Overseas Pharmaceuticals, Ltd., Shanghai ShouYan Clinical Development Co.,Ltd. | Idiopathic Pulmonary Fibrosis | 09/24 | 12/24 | | |
NCT06022354: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 84 | RoW | SIM0278 Injection/Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteers | 05/25 | 07/25 | | |
